28050 results about "Methyl palmoxirate" patented technology

A resist composition comprises a polymer comprising recurring units having formula (1) wherein R¹, R⁴, R⁷, and R¹⁴ are H or methyl, R², R³, R¹⁵, and R¹⁶ are H, alkyl or fluoroalkyl, R is F or H, R⁵ is alkylene, R⁶ is fluorinated alkyl, R⁸ is a single bond or alkylene, R¹⁰ and R¹¹ are H, F, methyl or trifluoromethyl, R¹² and R¹³ are a single bond, —O— or —CR¹⁸R¹⁹—, R⁹, R¹⁸, and R¹⁹ are H, F, methyl or trifluoromethyl, R¹⁷ is alkylene, X¹, X² and X³ are —C(═O)—O—, —O—, or —C(═O)—R²⁰—C(═O)—O— wherein R²⁰ is alkylene, 0≦(a-1)<1, 0≦(a-2)<1, 0≦(a-3)<1, 0<(a-1)+(a-2)+(a-3)<1, 0<b<1, and 0<(a-1)+(a-2)+(a-3)+b≦1.

Disclosed are mixtures and compositions for controlling invertebrate pests relating to combinations comprising (a) 3-bromo-N-[4-chloro-2-methyl-6-[(methylamino)carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide, and its N-oxides, and suitable salts thereof

and a component (b) wherein the component (b) is at least one compound or agent selected from neonicotinoids, cholinesterase inhibitors, sodium channel modulators, chitin synthesis inhibitors, ecdysone agonists, lipid biosynthesis inhibitors, macrocyclic lactones, GABA-regulated chloride channel blockers, juvenile hormone mimics, ryanodine receptor ligands, octopamine receptor ligands, mitochondrial electron transport inhibitors, nereistoxin analogs, pyridalyl, flonicamid, pymetrozine, dieldrin, metaflumizone, biological agents, and suitable salts of the foregoing. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a mixture or composition of the invention.

The invention relates to an aerogel composite material, in particular to a glass fiber reinforced silicon dioxide aerogel composite material and a preparation method thereof. The excellent properties of aerogel are maintained, the mechanical properties of the aerogel are reinforced, and the glass fiber reinforced silicon dioxide aerogel composite material has good integrity and certain strength. The glass fiber reinforced silicon dioxide aerogel composite material is prepared by compounding glass fiber and silicon dioxide aerogel, wherein the glass fiber is a reinforcement, and the content ofthe glass fiber accounts for 1-15% total mass of a sample; the silicon dioxide aerogel is a matrix, tetraethoxysilane is a silicon source material, and methyltrimethoxysilane or methyltriethoxysilaneis used as a silicon source co-precursor. The preparation method comprises the following steps of: firstly, pretreating the glass fiber; then, preparing glass fiber reinforced silicon dioxide composite wet gel; and finally, aging, secondarily modifying and drying the silicon dioxide composite wet gel.

A pharmaceutical composition comprising Compound 1, (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.

An environmentally clean dual fuel for an internal combustion engine, comprising acetylene as a primary fuel and a combustible fuel, such as one or more fluids selected from an alcohol such as ethanol, methanol or any other alcohol or alcohols from the group comprising C1-C20 carbon chains, ethers such as from the group comprising dimethyl ether, diethyl ether, methyl t-butyl ether, ethyl t-butyl ether, t-amyl methyl ether, di-isopropyl ether and the like, low-molecular-weight esters such as from the group comprising methyl formate, methyl acetate, ethyl acetate, methyl propionate, ethyl propionate and the like, or other suitable combustible fluid such as mineral spirits and the like, as a secondary fuel for operatively preventing early ignition and knock arising from the primary fuel. The dual fuel, internal combustion system, which generally utilizes a two-stage process for start-up and operation and can be operated with air- or liquid-cooling, is environmentally clean with hydrocarbon, CO, NOx, and SOx emissions substantially eliminated.

An environmentally-friendly cleaning composition for industrial and consumer applications comprising (a) a blend of dibasic esters, (b) one or more surfactants (c) and, optionally, (d) water or a solvent. The dibasic esters are be derived from a blend of adipic, glutaric, and succinic diacids, and, in one particular embodiment, the blend comprises dialkyl adipate, dialkyl methylglutarate and dialkyl ethylsuccinate, wherein the alkyl groups individually comprise a C₁-C₁₂ hydrocarbon group. The one or more surfactants are typically chosen from alcohol alkoxylate, an alkyl phenol ethoxylate, a terpene, a terpene alkoxylate or any derivates thereof. Optionally, additional components or additives including delaminates such as pinene and d-limonene, fragrances, whiteners, stabilizers, thickeners and the like can be added to the composition. The industrial or consumer application selected from the group consisting of a graffiti cleaner, a painted-substrate cleaner, an ink cleaner, a metal substrate cleaner, a plastic substrate cleaner, an environmentally friendly cleaner, a stain-spot cleaner, an industrial hand cleaner, a resin cleaner, a tar resin cleaner, a textile cleaner, a paint stripper and any combination thereof.

Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (-) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-alpha or the inhibition of PDE4.

A method of treating a treatment zone in a well to reduce the permeability of the treatment zone including the steps of: introducing into the treatment zone a water-based treatment fluid comprising: an aqueous silica sol; and a water-soluble chemical activator for gelling the silica sol, wherein the chemical activator is selected from the group consisting of: phytic acid, methylglycinediacetic acid, a water-soluble polyepoxysuccinic acid, salicylic acid, ascorbic acid, tannic acid, and an alkali metal salt or ammonium salt of any of the foregoing; and shutting in treatment zone for at least a sufficient time to allow the treatment fluid to in-situ form a solid gel at a design temperature for the method. Alternatively, a first treatment fluid including the aqueous silica sol and a second treatment fluid including the chemical activator can be introduced into the treatment zone separately, in any order.

A pharmaceutical composition comprises a drug-carrier system having a small-molecule drug of low water solubility, e.g. N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea (ABT-869), and (+)-1-(5-tert-butyl-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102), in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The drug-carrier system, when mixed with an aqueous phase, typically forms a non-gelling, substantially non-transparent liquid dispersion. The composition is suitable for administration by a suitable route, e.g. orally, to a subject in need thereof.

A nutritional supplement composition for normalizing impaired or deteriorating neurological function in humans is composed of: at least one agent which promotes synthesis of ATP and/or creatine phosphate in the body, at least one antioxidant for scavenging free radicals in at least one pathway in the body; at least one agent for normalizing or maintaining membrane function and structure in the body; at least one agent for normalizing or maintaining normal neurotransmitter function in the body; at least one agent for down-regulating cortisol action; and at least one agent for suppressing activation of apoptotic pathways in the body. The composition may further contain one or more of: at least one agent for suppressing inflammation in the body; at least one agent for normalizing or maintaining vascular wall function and structure in the body; at least one agent for normalizing or maintaining function of nerve growth factors and/or neurotropic factors in the body; at least one agent for suppressing toxic metal ionic effects; at least one agent for normalizing or maintaining methyl metabolism in the body; at least one agent for normalizing or maintaining metabolism of insulin and glucose in the body; and at least one agent for up-regulating activity of heat shock proteins in the body. A method for normalizing impaired neurological function in humans modulating nutrient partitioning in a human involves administering the aforementioned composition to the human, preferably on a daily basis, for a therapeutically effective period of time. Preferably, the method further involves having the human follow a stress reduction program, and/or a cognitive retraining program, and/or a dietary program designed to maximize insulin and glucose metabolism.

The present invention is directed to a method for preparing renewable and relatively high purity p-xylene from biomass. For example, biomass treated to provide a fermentation feedstock is fermented with a microorganism capable of producing a C₄ alcohol such as isobutanol, then sequentially dehydrating the isobutanol in the presence of a dehydration catalyst to provide a C₄ alkene such as isobutylene, dimerizing the C₄ alkene to a form one or more C₈ alkenes such as 2,4,4-trimethylpentenes or 2,5-dimethylhexene, then dehydrocyclizing the C₈ alkenes in the presence of a dehydrocyclization catalyst to selectively form renewable p-xylene in high overall yield. The p-xylene can then be oxidized to form terephthalic acid or terephthalate esters.

The present invention provides a compound of the formula:wherein Ar represents an aromatic group which may be substituted;X represents methylene, S, SO, SO2 or CO;Y represents a spacer having a main chain of 2 to 5 atoms;n represents an integer of 1 to 5;i) R1 and R2 each represents a hydrogen atom or a lower alkyl which may be substituted,ii) R1 and R2 form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted, oriii) R1 or R2 together with -(CH2)n-N= form, bonded to a component atom of Ring B, a spiro-ring which may be substituted;Ring A represents an aromatic ring which may be substituted;Ring B represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl,with a proviso that X represents S, SO, SO2 or CO when Ring A has as a substituent a group represented by the formula:where R11 represents alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group represented by the formula:where R12 represents alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or a salt thereof; which has an excellent somatostatin receptor binding inhibition action.

A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.

The invention discloses an olefin polymeric catalyst and preparing method and reacting technology, which is characterized by the following: the expression formula of catalyst is [SiO2-Cat], wherein Cat represents semi-sandwich homogeneous phase catalyst of transient element metallic titanium (IV) or zirconium (IV); SiO2 represents dielectric molecular sieve SBA-15 decorated by methyl alundum alkyl, which can synthesize polyethylene; the catalyst possesses high ethylene polymeric activity, which displays ultrahigh molecule with different patterns.

The invention discloses 2-pyridine-oxyl(sulfide) benzoyloxy enoates compound with general formula(I, II); wherein X is H or S; R1 is H, halogen, or 4,6- dimethoxy pyrimidine-2- radicel or one of the following groups; methyls on N-O bonds and double bonds are in maleinoid form or anti form; R2,R3,R4,R6,R7 are selected from H or alkyl from C1-C6; R5 is alkyl from C1-C6, alcoxyl-alkyl from C2-C6, alkenyl from C3-C6 or alkynyl from C3-C6; radicals of R6 and R7 are in maleinoid form or anti form; R8 is alkyl from C1-C6, alkenyl from C3-C6 or alkynyl from C3-C6. The compound (I, II)is of activity in weeding and is safe to crops like soybean, cotton, earthnut, cole, corn, etc.

The invention relates to a 4-benzoyl pyrazole compound with herbicidal activity. The structural formula of the 4-benzoyl pyrazole compound with the herbicidal activity is as shown in specifications, wherein R1 in the structural formula is selected from hydrogen, methyl or ethyl, R2 in the structural formula is selected from methylsulfonyl, methoxyl, methylthio, fluorine, chlorine or cyan, R3 in the structural formula is selected from hydrogen, methyl, methyl fluoride, difluoromethyl or trifluoromethyl, R in the structural formula is selected from a five-membered heteroaromatic ring, a six-membered heteroaromatic ring, C1-C6 alkoxyl, aromatic hetero-oxy, six-membered aryloxy or six-membered aromatic amino, and hydrogen in the C1-C6 alkoxyl can be replaced by fluorine or chlorine; m and n are selected from 0 or 1 and cannot be 1 at the same time. A series of relatively efficient weed killers and plant growth regulators with relative good selectivity and safety are synthesized by introducing a fluorine-containing functional group to a pyrazole 3-site and chemically modifying a pyrazole 5-site.

PCT No. PCT/US97/04957 Sec. 371 Date Mar. 24, 1999 Sec. 102(e) Date Mar. 24, 1999 PCT Filed Mar. 25, 1997 PCT Pub. No. WO97/36989 PCT Pub. Date Oct. 9, 1997Bleach compositions comprising a percarbonate bleach and an amino tricarboxylic acid exhibit a reduced tendency to deposit calcium carbonate insolubles on substrates being bleached. Laundry compositions comprising percarbonate bleach and methyl glycine diacetic acid are provided.

Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.